Clinical trials: Soft Tissue Sarcomas
Sarcoma, Liposarcoma
Patient Reported Outcome Measures (PROMs) With Trabectedin
Patient reported outcome measures (PROMs) are central to understanding the impact of cancer treatments on patients. Treatment may control cancer growth, and even sometimes modestly improve the length of life, but at the expense…
- Conditions
- Sarcoma, Liposarcoma, Leiomyosarcoma
- Trial name
- NCT03959033
- Where
- United Kingdom
- Volunteers
- 7 people
- Sponsor
- University of Leeds
Sarcoma
MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma
This study will evaluate the safety and preliminary efficacy of Multi-Antigen Stimulated Cell Therapy-I Injection (MASCT-I) in combination with Apatinib and/or Camrelizumab in patients with advanced bone and soft-tissue sarcoma.
- Trial name
- NCT04074564
- Testing
- MASCT-I, Camrelizumab,Apatinib
- Where
- China
- Volunteers
- 60 people
- Sponsor
- HRYZ Biotech Co.
High-Grade Osteosarcoma
Treatment Patterns and Survival Outcomes in High-Grade Osteosarcoma: A Multicenter Retrospective Study
This is a multicenter, medical-record-based, retrospective observational study of approximately 400 patients with high-grade osteosarcoma treated at four sites in the Republic of Korea.
- Trial name
- NCT07878364
- Where
- 4 sites in South Korea
- Volunteers
- 400 people
- Sponsor
- MedPacto, Inc.
Sarcoma, Osteoid Sarcoma
Combination Immunotherapy Targeting Sarcomas
The aim of this clinical trial is to assess the feasibility, safety and efficacy of a combination low dose chemotherapy and immunotherapy in patients who have sarcoma that is relapsed or late staged.
- Conditions
- Sarcoma, Osteoid Sarcoma, Ewing Sarcoma
- Trial name
- NCT04433221
- Testing
- Multiple sarcoma-specific CAR-T cells and sarcoma vaccines
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Shenzhen Geno-Immune Medical Institute
Metastatic Esophageal, Gastric Cancer
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
This is an investigator-initiated industry-supported phase 1 clinical trial conducted in the phase 1 clinic at The University of Texas MD Anderson Cancer Center who will hold the Investigational New Drug (IND).
- Conditions
- Metastatic Esophageal, Gastric Cancer, Metastatic Head and Neck Carcinoma, Metastatic Hepatocellular Carcinoma
- Trial name
- NCT05075993
- Testing
- LVGN3616 + LVGN6051 + Nab-Paclitaxel, LVGN3616 + LVGN6051 + Bevacizumab + Cyclophosphamide, LVGN3616 + LVGN6051 + LVGN7409 + Nab-Paclitaxel
- Where
- United States
- Volunteers
- 352 people
- Sponsor
- M.D. Anderson Cancer Center
Solid Tumor, Adult, Soft Tissue Sarcoma
Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors
This study evaluates the safety and efficacy of AL3818 (anlotinib) hydrochloride in combination with Opdivo (nivilumab) for the treatment patients with of metastatic, advanced, or recurrent solid tumors.
- Conditions
- Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer, Small Cell Lung Cancer
- Trial name
- NCT04165330
- Testing
- AL3818, Nivolumab Injection
- Where
- United States
- Volunteers
- 56 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Soft Tissue Sarcoma
Circulating Tumor DNA in Soft Tissue Sarcoma
This research study will collect blood and tumor tissue samples from patients with soft tissue sarcoma to look at circulating tumor deoxyribonucleic acid (DNA).
- Trial name
- NCT03818412
- Testing
- Archival tumor tissue collection and blood draws
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- University Health Network, Toronto
Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma
First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma
The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.
- Trial name
- ADCElerate1 (NCT06797999)
- Testing
- Antibody-drug conjugate (ADC)
- Where
- 9 sites in United States, Belgium and 3 more
- Volunteers
- 270 people
- Sponsor
- Adcendo ApS
Breast Cancer, Gestational Trophoblastic Tumor
Interleukin-11 Plus Filgrastim Prior to Peripheral Stem Cell Transplantation in Patients With Non-Hodgkin's Lymphoma, Hodgkin's Disease, Breast Cancer, or Other Solid Tumors
RATIONALE: Interleukin-11 and filgrastim stimulate the production of blood cells. Giving these drugs to stimulate peripheral stem cells that can be collected for peripheral stem cell transplantation may result in fewer side…
- Conditions
- Breast Cancer, Gestational Trophoblastic Tumor, Kidney Cancer, Lymphoma
- Trial name
- NCT00004157
- Testing
- filgrastim, recombinant interleukin-11
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Sarcoma
Pharmacometabolomic of Trabectedin in Soft Tissue Patients
This perspective, mono institutional study is addressed to find potential serum and urine biomarkers predictive of the pharmacokinetic and pharmacodynamic profile of soft tissue sarcomas patients treated with trabectedin.
- Trial name
- Metabol-STS (NCT04394728)
- Testing
- Trabectedin
- Volunteers
- 44 people
- Sponsor
- Centro di Riferimento Oncologico - Aviano
Sarcoma
Three Versus Five Years of Adjuvant Imatinib as Treatment of Patients With Operable GIST
In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) and have been treated with adjuvant imatinib for 3 years after surgery will be randomly allocated in a 1:1 ratio to receive imatinib…
- Trial name
- NCT02413736
- Testing
- Imatinib
- Where
- Finland
- Volunteers
- 255 people
- Sponsor
- Heikki Joensuu
Osteosarcoma
Mifamurtide Combined With Post-operative Chemotherapy for Newly Diagnosed High Risk Osteosarcoma Patients
Trial evaluating the impact on efficacy of mifamurtide as add-on treatment to post-operative chemotherapy compared to post-operative chemotherapy alone in first-line treatment of patients with high-risk osteosarcoma (defined as…
- Trial name
- SARCOME13 (NCT03643133)
- Testing
- Mifamurtide, EI or M-API regimen depending on patient age
- Where
- 31 sites in France
- Volunteers
- 60 people
- Sponsor
- UNICANCER
Sarcoma
Doxorubicin Plus External-Beam Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004109
- Testing
- Doxorubicin Hydrochloride, Radiation Therapy (RT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- M.D. Anderson Cancer Center
Clear Cell Sarcoma (CCS)
Vebreltinib for Advanced or Metastatic CCS
This is a prospective, cohort, multicenter study. Cohort 1 is treatment group. All eligible subjects will receive Vebreltinib (200 mg bid po) after signing the informed consent and meeting the inclusion/exclusion criteria, until…
- Trial name
- NCT07153887
- Testing
- Vebreltinib, Standard medical treatment
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Acute Radiation Dermatitis, Head and Neck Cancer (H&N)
Effectiveness of 0.9% Normal Saline Soaking in Managing Acute Radiation Dermatitis
The goal of this clinical trial is to learn if normal saline soaks can reduce the severity of acute radiation dermatitis in patients with sarcomas or head and neck cancer receiving radiotherapy.
- Conditions
- Acute Radiation Dermatitis, Head and Neck Cancer (H&N), Sarcomas
- Trial name
- NCT07553260
- Testing
- Normal Saline Soaks (0.9% Sodium Chloride)
- Where
- Jordan
- Volunteers
- 150 people
- Sponsor
- King Hussein Cancer Center
Glioblastomas, Gliosarcoma
Hyperbaric Hyperoxygenation With Radiotherapy and Temozolomide in Adults With Newly Diagnosed Glioblastoma
Standard treatment for glioblastomas includes radiation and chemotherapy with a drug called temozolomide (Temodar); however, glioblastomas frequently develop resistance to standard treatment and recur or progress.
- Trial name
- HBO (NCT00936052)
- Testing
- Hyperbaric Oxygen Therapy
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Neurological Surgery, P.C.
Sarcoma
Troglitazone in Treating Patients With Liposarcoma
Troglitazone may help liposarcoma cells develop into normal cells. This was a single arm, open-label study with a two-stage design to evaluate troglitazone in patients with liposarcoma stratified by histologic subtype.
- Trial name
- NCT00003058
- Testing
- troglitazone
- Where
- 2 sites in United States
- Volunteers
- 85 people
- Sponsor
- Dana-Farber Cancer Institute
Osteosarcoma, Metastatic Bone Disease
Musculoskeletal Cancers Remote Monitoring and Care
This study aims to evaluate how walking stability and the ability to perform daily activities change during cancer treatment, and whether a smartwatch can detect these changes.
- Trial name
- NCT07129226
- Testing
- Smart Watch
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Case Comprehensive Cancer Center
Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma
Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
This study compares the outcomes and safety of two standard treatment options called microwave ablation and surgical wedge resection in patients with non-small cell lung cancer, sarcoma and colorectal cancer that has spread to…
- Conditions
- Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Sarcoma, Stage I Lung Cancer AJCC v8
- Trial name
- NCT04430725
- Testing
- Computed Tomography with Contrast, Microwave Ablation, Questionnaire Administration
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- M.D. Anderson Cancer Center
Fabry Disease, Cardiac Variant, Right Ventricular Hypertrophy
Myocardial Affectation in Patients With Fabry Disease Without Phenotypic Manifestation. Diagnostic Value of Biomarkers
The cardiac variant of the Fabry disease is a rare cardiomyopathy affecting 1/50000 individuals in general population. It is generally diagnosed in advanced stages of the disease, because it presents clinical features very…
- Trial name
- FAMY (NCT01442350)
- Volunteers
- 120 people
- Sponsor
- Francisco Marín Ortuño